Claim Amendments

A listing of the claims, including Claim 117 as amended and Claim 120 as canceled herein is set forth below.

1-116.  (Canceled)

117.  (Currently Amended)  A method of

(a) determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells, or

(b) following the progression of treatment of B-CLL in a patient having a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells,

the method comprising determining whether ~~the~~ a B cell receptors on ~~the~~ a B-CLL ~~cells~~ from the patient is ~~are~~ encoded by antibody genes comprising a light chain antibody gene and a heavy chain antibody gene, wherein the light chain antibody gene and the heavy chain antibody gene are selected from the group consisting of ~~$V_H4-39/D6-13/J_H5/V_L\kappa O12/2/J_L\kappa1/\kappa2$ (Set I),~~ $V_H4-34/D5-5/J_H6/V_L\kappa A17/J_L\kappa1/\kappa2$ (Set II), $V_H3-21/J_H6/V_L\lambda3h/J_L\lambda3$ (Set III), $V_H1-69/D3-16/J_H3/V_L\kappa A27/J_L\kappa1/\kappa4$ (Set IV), $V_H1-69/D3-10/J_H6/V_L\lambda1c/J_L\lambda1$ (Set V), $V_H1-02/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa1/\kappa2$ (Set VIa), $V_H1-03/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa1/\kappa2$ (Set VIb), $V_H1-18/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa1$ (Set VIc), $V_H1-46/D6-19/J_H4$ (Set VId), $V_H5-51/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa2$ (Set VIe), $V_H1-69/D3-3/J_H4/V_L\kappa A19/J_L\kappa4$ (Set VII), and $V_H1-69/D2-2/J_H6/V_L\kappa L6/2/J_L\kappa3$ (Set VIII),

wherein if the B cell receptors on the B-CLL cells ~~have~~ has an idiotype encoded by the antibody genes, the patient has a form of B-CLL susceptible to ~~the~~ treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells or the treatment of the patient has not eliminated the idiotype-specific B cell receptor-bearing B-CLL cells.

118.   (Previously Presented)  The method of claim 117, for determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells.

119.   (Previously Presented)  The method of claim 117, for following the progression of treatment of B-CLL in a patient having a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells.

120.   (Canceled)

121.   (Previously Presented)  The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H4-34/D5-5/J_H6/V_L\kappa A17/J_L\kappa 1/\kappa 2$ (Set II).

122.   (Previously Presented)  The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H3-21/J_H6/V_L\lambda 3h/J_L\lambda 3$ (Set III).

123.   (Previously Presented)  The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-69/D3-16/J_H3/V_L\kappa A27/J_L\kappa 1/\kappa 4$ (Set IV).

124.   (Previously Presented)  The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-69/D3-10/J_H6/V_L\lambda 1c/J_L\lambda 1$ (Set V).

125.   (Previously Presented)  The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-02/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa 1/\kappa 2$ (Set VIa).

126.   (Previously Presented)  The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-03/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa 1/\kappa 2$ (Set VIb).

127.    (Previously Presented)    The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-18/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa 1$ (Set VIc).

128.    (Previously Presented)    The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-46/D6-19/J_H4$ (Set VId).

129.    (Previously Presented)    The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H5-51/D6-19/J_H4/V_L\kappa O12/2/J_L\kappa 2$ (Set VIe).

130.    (Previously Presented)    The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-69/D3-3/J_H4/V_L\kappa A19/J_L\kappa 4$ (Set VII).

131.    (Previously Presented)    The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is $V_H1-69/D2-2/J_H6/V_L\kappa L6/2/J_L\kappa 3$ (Set VIII).

132.    (Previously Presented)    The method of claim 117, wherein the patient is pre-leukemic.

133.    (Previously Presented)    The method of claim 117, wherein the patient is in an early leukemic state.

134.    (Previously Presented)    The method of claim 117, wherein the patient is in a frank leukemic state.

135.    (Previously Presented)    The method of claim 117, wherein the B-CLL cells from blood of the patient are evaluated.